Glycerol-3-phosphate acyltransferase 1, mitochondrial (GPAM)

Glycerol-3-phosphate acyltransferase 1, mitochondrial (GPAM) is an enzyme located in the mitochondrial outer membrane that catalyzes the first and rate-limiting step in glycerolipid biosynthesis: the acylation of glycerol-3-phosphate with long-chain acyl-CoA to produce lysophosphatidic acid[1][2][3][5]. GPAM is especially active with saturated fatty acids and is highly expressed in liver and adipose tissues, playing a major role in triglyceride and phospholipid synthesis and regulating systemic energy homeostasis[3][5]. It influences biological processes including adipocyte differentiation, lipid metabolism, immune cell function, and disease susceptibility, particularly impacting metabolic disorders, liver disease, and insulin resistance[1][3]. GPAM activity is controlled by both transcriptional and post-transcriptional mechanisms involving key metabolic regulators such as SREBP-1c, ChREBP, LXR, insulin, and AMPK[1].

Other names

GPAT1GPAT-1KIAA1560MGC26846Glycerol-3-phosphate acyltransferase, mitochondrialGPAMGPATGlycerol-3-phosphate acyltransferase 1, mitochondrial

Drugs or modulators targeting GPAM (not named in the results) work by inhibiting or activating its enzymatic activity, thereby altering lipid synthesis and downstream cellular energy metabolism[1][3].